257 results on '"Donohue, James"'
Search Results
2. The Most Important Words of Jesus. By Gerhard Lohfink. Translated by Linda M. Maloney. Collegeville, MN: Liturgical Press, 2023. xviii + 340 pages. $34.95.
3. INSIGHTS INTO TREATMENT PATTERNS AND SHARED DECISION-MAKING AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4. Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science
5. Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD
6. Confessions of a Priest
7. Effects of Osteopathic Training and Medical Simulation on Lumbar Puncture Landmark Identification in American Medical Students
8. Teaching of Concepts
9. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease
10. Practical Sacramental Theology: At the Intersection of Liturgy and Ethics. By Bruce T. Morrill. Eugene, OR: Cascade Books, 2021. viii + 176 pages. $24.00 (paper).
11. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
12. There’s something about a pattern: Choice between pattern and random sequences in implicit learning.
13. Respiratory Symptoms among US Adults: a Cross-Sectional Health Survey Study
14. Conservation of Kidney Development in the Red‐eared Slider, Trachemys scripta
15. Respiratory Symptoms Among US Adults
16. Reading Revelation at Easter Time. By Francis J. Moloney SDB. Collegeville, MN: Liturgical Press, 2020. xix + 197 pages. $24.95 (paper).
17. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update
18. FEV1 Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn
19. Future concepts in bronchodilation for COPD: dual- versus monotherapy
20. Current Pharmacotherapy for COPD
21. Contributeurs
22. Maladie pulmonaire obstructive chronique
23. Contributors
24. Chronic Obstructive Pulmonary Disease
25. Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD
26. Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important
27. Using semantic waves to analyse the effectiveness of unplugged computing activities
28. IMPROVEMENTS IN HEALTH STATUS WITH REVEFENACIN: A POST HOC ANALYSIS OF ST GEORGE’S RESPIRATORY QUESTIONNAIRE IN PATIENT SUBGROUPS FROM REPLICATE PHASE 3 TRIALS
29. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
30. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
31. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
32. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
33. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
34. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
35. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
36. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
37. Confession: Catholics, Repentance, and Forgiveness in America. By Patrick W. Carey. New York: Oxford University Press, 2018. xiv + 375 pages. $34.95.
38. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
39. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
40. Regexes are Hard: Decision-Making, Difficulties, and Risks in Programming Regular Expressions
41. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
42. Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease
43. Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
44. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
45. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective
46. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease
47. Arterial Variation in the Upper Extremity Observed During Cadaveric Dissection
48. Direct Aortic Origin of the Left Vertebral Artery in Two Adult Female Cadavers
49. Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
50. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.